Maynard Um
-
-
-
-
-
-
-
Needham on Neogenomics (NEO): 'Stronger NGS Growth Drove Upside in 1Q26'
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on Neogenomics (NEO): reimbursements 'could drive '26 revenue growth 3-4% higher'
-
-
-
-
-
-
-
NeoGenomics reports preliminary Q4 revenue of $190 million, CFO transition
-
-
-
-
-
-
-
Neogenomics (NEO) PT Raised to $11 at Stephens
-
-
-
-
-
-
-
William Blair Downgrades Neogenomics (NEO) to Market Perform
-
-
-
-
-
-
-
NeoGenomics (NEO) and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform
-
-
-
-
-
-
-
BTIG Reiterates Buy Rating on Neogenomics (NEO)
-
444,311 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

